Compare Amgen, Inc. (AMGN) vs iShares Self-Driving EV and Tech (IDRV) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs iShares Self-Driving EV and Tech — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while iShares Self-Driving EV and Tech trades at $36.65. The key difference: Amgen, Inc. pays a 2.77% dividend while iShares Self-Driving EV and Tech pays none, and Amgen, Inc. is trading nearer its 52-week high, iShares Self-Driving EV and Tech nearer its low. Which is the better fit depends on your goals.
| AMGN | IDRV | |
|---|---|---|
Market Cap | $196.12B | — |
Sector | Health | Sector/Thematic |
52-Week High | $388.16 | $45.48 |
52-Week Low | $271.18 | $32.13 |
Enterprise Value | $241.41B | — |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
IDRV trades at $36.86 with a slight 0.33% daily gain, but technical indicators signal a bearish trend with 19 sell signals versus 3 buys. The stock faces resistance at $37-$38 while finding support at $35-$36. Recent news highlights strong global EV sales growth, particularly in China and Europe, though U.S. adoption remains slower. Key financial ratios including P/E, P/S, and ROE are currently unavailable for analysis.
The EV sector shows promising growth catalysts from rising fuel prices and expanding global adoption, but IDRV faces technical headwinds and competitive pressures. Investment appeal depends on improved fundamental metrics and sector momentum overcoming current bearish technical positioning. Regulatory developments and Chinese market expansion present both opportunities and risks for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About iShares Self-Driving EV and Tech
IDRV invests in global companies at the forefront of self-driving and electric vehicle innovation. It provides exposure to the full EV value chain, including battery technology and autonomous systems, with top holdings like Albemarle, Rivian, and Tesla.
Read more on IDRV →
